A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)

S‐1 and irinotecan combination is attractive for breast cancer refractory to anthracyclines and taxanes. Patients with advanced human epidermal growth factor receptor 2 (HER2)‐negative breast cancer previously treated with anthracyclines and taxanes were eligible. Patients with brain metastases and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishiguro, Hiroshi, Saji, Shigehira, Nomura, Shogo, Tanaka, Sunao, Ueno, Takayuki, Onoue, Masahide, Iwata, Hiroji, Yamanaka, Takeharu, Sasaki, Yasutsuna, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727322/
https://www.ncbi.nlm.nih.gov/pubmed/29131533
http://dx.doi.org/10.1002/cam4.1258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727322/
https://www.ncbi.nlm.nih.gov/pubmed/29131533
http://dx.doi.org/10.1002/cam4.1258

Ejemplares similares